


WHAT IS CLAIMED IS:

1. (currently amended) A compound having the formula I:



I

in which:

Ring A is a (C₃-C₈)-cycloalkanediyl ring or a (C₃-C₈)-cycloalkenediyl ring,

R1 and R2 are:

- (a) Independently of one another H, F, Cl, Br, CF₃, OCF₃, (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl, SCF₃, SF₅, OCF₂-CHF₂, (C₆-C₁₀)-aryl, (C₆-C₁₀)-aryloxy, OH, NO₂; or
- (b) together with the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form fused, partially or unsaturated bicyclic (C₆-C₁₀)-aryl, (C₅-C₁₁)-heteroaryl;

R3 is:

H, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, (C₁-C₃)-alkyl-(C₃-C₈)-cycloalkyl, phenyl, (C₁-C₃)-alkyl-phenyl, (C₅-C₆)-heteroaryl, (C₁-C₃)-alkyl-(C₅-C₆)-heteroaryl, or (C₁-C₃)-alkyl fully or partially substituted by F;

W is:

- (a) is CH and o = 1, or
- (b) is O, S or NR10 if o = 0;

X is (C₁-C₆)-alkanediyl, wherein one or more carbon atoms of the (C₁-C₆) alkanediyl may be replaced by oxygen atoms;

Y1 is (CR13R14)_p, wherein p is 1 or 2;

Y2 is CH₂, O, S, SO, SO₂ or NR9;

n is 0-2;

R4 is H, (C₁-C₆)-alkyl; F if Y2 is not O; NR9;

R5 is H, (C₁-C₆)-alkyl; F if Y2 is not O; NR9;

R6 is H, (C₁-C₆)-alkyl; or F if n is not 0;

R7 is:

H, F (if n is not 0), (C₁-C₆)-alkoxy, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₈)-cycloalkyl, (C₁-C₆)-alkyl that may be unsubstituted or substituted by one or more radicals selected from the group consisting of:

hydroxyl, phenyl, (C₅-C₁₁)-heteroaryl, (C₁-C₆)-alkoxy and NR11R12, or phenyl that may be unsubstituted or substituted by one or more radicals from the group consisting of hydroxy, (C₁-C₆)-alkoxy, F and CF₃,

with the proviso that R7 is not NR11R12 or (C₁-C₆)-alkoxy if R6 = F;

R6 and R7 are together with the carbon atom that carries them (C₃-C₈)-cycloalkyl;

R8 is H or (C₁-C₆)-alkyl;

R9 is:

H, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, aryl-(C₁-C₄)-alkyl, CO-(C₁-C₆)-alkyl, CO-(C₆-C₁₀)-aryl, CO-(C₁-C₆)-alkyl-(C₆-C₁₀)-aryl, CO-(C₅-C₁₁)-heteroaryl, C(O)-O-(C₁-C₆)-alkyl, C(O)-O-(C₁-C₆)-alkyl-(C₆-C₁₀)-aryl, C(O)-O-(C₆-C₁₀)-aryl, C(O)-O-(C₅-C₁₁)-heteroaryl, SO₂-(C₁-C₆)-alkyl, SO₂-(C₁-C₆)-alkyl-(C₆-C₁₀)-aryl, SO₂-(C₁-C₆)-alkyl-SO₂-(C₁-C₆)-alkyl, SO₂-(C₆-C₁₀)-aryl, SO₂-(C₅-C₁₁)-heteroaryl, wherein aryl or heteroaryl, or both may be unsubstituted or substituted by (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl, F, Cl, CO-(C₁-C₆)-alkyl;

R10 is H, (C₁-C₆)-alkyl or (C₁-C₆)-alkyl-phenyl;

R11 is H, (C₁-C₆)-alkyl or (C₁-C₆)-alkyl-phenyl;

R12 is H, (C₁-C₆)-alkyl or (C₁-C₆)-alkyl-phenyl;

R13 is H or (C₁-C₆)-alkyl; and

R14 is H or (C₁-C₆)-alkyl; or

a physiologically acceptable salt of the compound;

a solvate of the compound; or

a physiologically active derivative of the compound.

2. (original) The compound of claim 1 in which

Ring A is (C₃-C₈)-cycloalkanediyl or (C₃-C₈)-cycloalkenediyl, wherein one carbon atom of the (C₃-C₈)-cycloalkanediyl ring or the (C₃-C₈) cycloalkenediyl ring may be replaced by an oxygen atom; and

X is (C₁-C₆)-alkanediyl, wherein the C₁ or C₂ carbon atom (to Ring A) may be replaced by an oxygen atom.

3. (original) The compound of claim 1, in which

Ring A is cis-cyclohexane-1,3-diyl;

R1 and R2 are:

independently of one another H, F, CF₃, (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl, or phenyl; or

together with a phenyl ring of the compound form a naphthyl;

R3 is (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, or phenyl;

W is:

CH if o = 1, or

O or S if o = 0;

X is CH₂-O or CH₂-O-CH₂;

Y1 is CH₂;

Y2 is CH₂, O, S, SO, SO₂ or NR₉;

n is 0;

R4 is H;

R5 is H;

R6 is H, (C₁-C₆)-alkyl, or benzyl;

R7 is H, (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, phenyl, or benzyl,

R6 and R7 together with the carbon atom that carries them are (C₃-C₆)-cycloalkyl;

R8 is H; and

R9 is:

H, or

(C₁-C₆)-alkyl, which may be unsubstituted or substituted by:

(C₃-C₆)-cycloalkyl, phenyl, (C₅-C₆)-heteroaryl; CO-(C₁-C₆)-alkyl, CO-(C₁-C₆)-alkyl-phenyl, CO-phenyl, C(O)-O-(C₁-C₆)-alkyl, CO-NH-phenyl, SO₂-(C₁-C₄)-alkyl, SO₂-(C₁-C₄)-alkyl-SO₂-(C₁-C₄)-alkyl, SO₂-tolyl, or a combination thereof, wherein the phenyl of the substituent for its part may be substituted by O-(C₁-C₃)-alkyl;

a physiologically acceptable salt of the compound;

a solvate of the compound; or

a physiologically acceptable derivative of the compound.

4. (original) A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.

5. (original) The pharmaceutical composition of Claim 4, further comprising an active compound for treating and/or preventing a metabolic disorder or a disease associated with the metabolic disorder.

6. (original) The pharmaceutical composition of Claim 4, further comprising an antidiabetic.

7. (original) The pharmaceutical composition of Claim 4, further comprising a lipid modulator.

8. -15. (withdrawn)

16. (original) The compound of Claim 2, in which

Ring A is cis-cyclohexane-1,3-diyl;

R1 and R2 are:

independently of one another H, F, CF₃, (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl, or phenyl; or together with a phenyl ring of the compound form a naphthyl;

R3 is (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, or phenyl;

W is:

CH if o = 1, or

O or S if o = 0;

X is CH₂-O or CH₂-O-CH₂;

Y1 is CH₂;

Y2 is CH₂, O, S, SO, SO₂ or NR₉;

n is 0;

R4 is H;

R5 is H;

R6 is H, (C₁-C₆)-alkyl, or benzyl;

R7 is H, (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, phenyl, or benzyl,

R6 and R7 together with the carbon atom that carries them are (C₃-C₆)-cycloalkyl;

R8 is H; and

R9 is:

H, or

(C₁-C₆)-alkyl, which may be unsubstituted or substituted by:

(C₃-C₆)-cycloalkyl, phenyl, (C₅-C₆)-heteroaryl; CO-(C₁-C₆)-alkyl, CO-(C₁-C₆)-

alkyl-phenyl, CO-phenyl, C(O)-O-(C₁-C₆)-alkyl, CO-NH-phenyl, SO₂-(C₁-C₄)-alkyl, SO₂-(C₁-C₄)-alkyl-SO₂-(C₁-C₄)-alkyl, SO₂-tolyl, or a combination thereof, wherein the phenyl of the substituent for its part may be substituted by O-(C₁-C₃)-alkyl;

a physiologically acceptable salt of the compound;

a solvate of the compound; or

a physiologically acceptable derivative of the compound.

17.-23. (withdrawn)

24. (original) A pharmaceutical composition comprising the compound of Claim 2 and a pharmaceutically acceptable carrier.

25. (original) A pharmaceutical composition comprising the compound of Claim 3 and a pharmaceutically acceptable carrier.

26. (original) A pharmaceutical composition comprising the compound of Claim 16 and a pharmaceutically acceptable carrier.

Respectfully submitted,



Craig M. Bell Reg. No. 31,812
Attorney for Applicant
Reg. No. 31,812

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2387
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2003/0082 US NP